Rapid-onset Hypoglycemic Effect of Mitiglinide Calcium Dihydrate (KAD-1229), a Novel Antipostprandial-hyperglycemia Agent-Comparison with Glimepiride-
|
Accession number;04A0411200
|
| Title;Rapid-onset Hypoglycemic Effect of Mitiglinide Calcium Dihydrate (KAD-1229), a Novel Antipostprandial-hyperglycemia Agent-Comparison with Glimepiride- |
| Author;
OJIMA KAZUMA
(Kisseiyakuhinkogyo Yakuriken)
NAGASAWA TATSUYA
(Kisseiyakuhinkogyo Anzenseiken)
OTA MASANAO
(Kisseiyakuhinkogyo Anzenseiken)
OKUHARA YUJI
(Kisseiyakuhinkogyo Anzenseiken)
KOBAYASHI MAIKO
(Kisseiyakuhinkogyo Anzenseiken)
AOYAGI IKUMI
(Kisseiyakuhinkogyo Yakuriken)
FUJIMORI YOSHIKAZU
(Kisseiyakuhinkogyo Yakuriken)
ICHIKAWA KIYOSHI
(Kisseiyakuhinkogyo Yakuriken)
SHIBATA NOBUO
(Kisseiyakuhinkogyo Kaihatsukenkyubu)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.32;NO.3;PAGE.161-167(2004)
|
| Figure&Table&Reference;FIG.6, REF.17 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Objectives: The purpose of the present study was to evaluate the hypoglycemic effect of mitiglinide calcium dihydrate (KAD-1229), a novel antipostprandial-hyperglycemia agent, by comparing it with that of glimepiride, a sulfonylurea agent. Methods: In fasted beagle dogs, KAD-1229 (0.15, 0.3mg/kg) or glimepiride (0.03, 0.06mg/kg) was administered orally either with no load or just before an oral glucose load. Blood samples were taken from the cephalic vein for the determination of plasma glucose levels. In experiments with no load, plasma insulin levels were also measured. Results: With no glucose load, the hypoglycemic effect of KAD-1229 had a faster onset (at 0.25 h) than that of glimepiride (at 1 h), and a shorter duration (0.25-1 h) than that of glimepiride (1-8 h). KAD-1229 stimulated insulin secretion, the peak level occurring within 0.25 h and a return to baseline within 1 h. In contrast, the peak insulin level occurred at 1 h post-dose in the glimepiride groups. In the oral glucose tolerance test, KAD-1229 rapidly inhibited the increase in plasma glucose (at 0.25 h), and its effect had disappeared within 2 h after its administration. Glimepiride induced a lowering of the plasma glucose level at 1 h after its administration, and at a dose of 0.06mg/kg, the glucose level given did not return to control values within 8 h. Conclusion: The hypoglycemic effect of KAD-1229 was clearly faster in onset- and shorter lasting than that of glimepiride. KAD-1229 can be expected to be more effective than glimepiride at normalising postprandial hyperglycemia. (author abst.) |
|
|
|
Related Articles;
|
|
